Hancock Jaffe News Today

Chronic Venous Insufficiency typically refers to lower extremity edema, skin trophic changes, and discomfort secondary to venous hypertension....

Gainers Lixte Biotech Holdings (NASDAQ:LIXT) shares moved upwards by 16.45% to $3.75 during Tuesday’s after-market session. Today’s trading volume for this security ended up closing at 1.0 million shares, which is 100.31 percent of its average volume over the last 100 days. The company’s market cap stands at $51.2 million. Repro-Med Systems (NASDAQ:KRMD) shares moved upwards by 6.45% to $4.45. Trading volume for this security closed at 4.8K, accounting for 1.34% of its average full-day v...

Provided by Accesswire Apr 23, 2021 4:40 PM UTC IRVINE, CA / ACCESSWIRE / April 23, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLIs first-in-human VenoValve® study in Bogota, Colombia, presented one year data this past week at the Charing Cross International Symposium. The Charing Cross International Symposium is ...

Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium April 23, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLIs first-in-human VenoValve® study in Bogota, Colombia, presented one year data this past we...

Hancock Jaffe Laboratories, Inc.: First U.S. Patent Issues on Hancock Jaffe VenoValve / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the United States Patent and Trademark Office (USPTO) has issued the first patent covering the companys VenoValve. The patent is entitled Implantable Vein Frame and is U.S. patent number 10,959,841. The company recently announced that only twenty-eight (28) days aft...

Hancock Jaffe Laboratories, Inc.: First U.S. Patent Allowed on Hancock Jaffe VenoValve IRVINE, CA / ACCESSWIRE / February 24, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent covering the companys VenoValve. The patent, which focuses on novel aspects of the VenoValve frame, will be the ...

Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA IRVINE, CA / ACCESSWIRE / January 12, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has successfully concluded its VenoValve Pre-IDE meeting with the U.S. Food and Drug Administration ("FDA"). Topics presented at the meeting included the background and clinical need for the VenoValve, pr...

Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Reports Two CoreoGraft Patients Have Reached 30 Day Milestone IRVINE, CA / ACCESSWIRE / December 16, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that two patients who have undergone heart bypass surgeries utilizing HJLIs CoreoGraft have reached the 30-day milestone and are reported to have good cardiac function. The first two CoreoGraft surgeries w...

Share: IRVINE, CA / ACCESSWIRE / December 15, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the final aggregated data for the VenoValve first-in-human trial shows significant improvements in all study endpoints. For the eleven patients in the first-in-human study, reflux (the backwards flow of blood) improved an average of 54%, disease manifestations as measured by a venous clin...

Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Announces Significant Improvements in all Study Endpoints For Final VenoValve First-in-Human Data IRVINE, CA / ACCESSWIRE / December 15, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the final aggregated data for the VenoValve first-in-human trial shows significant improvements in all study endpoints. For the eleven patients in the...